As discussed earlier, Eli Lilly’s (LLY) 1Q16 segment-wise performance was positive for both its human pharmaceuticals and animal health segments. In this article, we’ll discuss some of the key developments during the quarter.
The commercial developments for Eli Lilly during 1Q16 include the following:
- Humulin R U-500 KwikPen launched in the US markets.
- Taltz, a drug for the treatment of plaque psoriasis, launched in the US markets.
- Cyramza, an oncology drug used in the treatment of advanced or metastatic non-small cell lung cancer and metastatic colorectal cancer, was launched in the European markets.
- Portrazza, a drug for the treatment of EGFR expressing squamous non-small cell lung cancer, launched in the European markets.
The significant regulatory developments for Eli Lilly in 1Q16 are as follows:
- The US Food and Drug Administration (or FDA) approved Taltz injection for the treatment of plaque psoriasis.
- Ixekizumab, the international non-proprietary name of Taltz, received approval from the European Commission for the treatment of plaque psoriasis.
- Baricitinib once-daily drug for the treatment of rheumatoid arthritis was submitted for approvals in Japan.
- Olaratumab, the drug for treatment of soft tissue sarcoma, was submitted for approval in the US and Europe.
- Imrestor, a protein alternative to antibiotics, was approved for the reduction of clinical mastitis in cows in the US.
Investors can consider ETFs like the Vanguard Healthcare ETF (VHT), which holds ~2.2% of its total assets in Eli Lilly, ~6.1% of its total assets in Pfizer (PFE), ~4.9% of its total assets in Merck (MRK), and ~3.1% of its total assets in AbbVie (ABBV). Investors can also consider the iShares US Pharmaceuticals ETF (IHE), which holds ~5.8% of its total assets in Eli Lilly, in order to divest company-specific risk.